Steglashit

Quote
























Didn't expect the end to be so close so soon! Sales are anemic for Belsomra and the Steglashit family. Januvia Family sales are sliding. Dulera and the rest of the pack are at the end of the rainbow with a pot of piss waiting for the reps. Clock is definitely ticking for us.
 






Don’t despair folks! Keytruda holds the key! The key to Merck’s success now - and for the future. People will pay up the wazoo for that med ‘cuz “Ya’ wanna live - don’t ya’?”
 






anonymous said:
Didn't expect the end to be so close so soon! Sales are anemic for Belsomra and the Steglashit family. Januvia Family sales are sliding. Dulera and the rest of the pack are at the end of the rainbow with a pot of piss waiting for the reps. Clock is definitely ticking for us.
Click to expand...
Januvia sales are solid. Still garnering majority of market. Why is Steglatro doing poorly.
 






Januvia is doing very well. Fortunately, latest data on Steglatro is very very good bordering great. Great marketing message. Really impressed with this entire promotion. The decision to change territories and let relationships with physicians that had been built over many years be dissolved was a great one.
 












anonymous said:
Januvia is doing very well. Fortunately, latest data on Steglatro is very very good bordering great. Great marketing message. Really impressed with this entire promotion. The decision to change territories and let relationships with physicians that had been built over many years be dissolved was a great one.
Click to expand...

You’re just upset because you can’t sell. You were taken out of your comfort zone and are now being seen for your true “selling” abilities.
 
















































I checked Gator this week. The other SGLT2s are now starting to see what Merck can do in diabetes. All other SGLT2 companies are very concerned about the latest trends with Steglatro. This is fun. These other drugs are becoming very easy to take market share from. Januvia has given us a tremendous in to gaining Steglatro business
 






anonymous said:
I checked Gator this week. The other SGLT2s are now starting to see what Merck can do in diabetes. All other SGLT2 companies are very concerned about the latest trends with Steglatro. This is fun. These other drugs are becoming very easy to take market share from. Januvia has given us a tremendous in to gaining Steglatro business
Click to expand...
The sky is the limit for Steglatro
 






Hate to break it to you Merck folks but Steglatro isn’t on anyone’s radar. The days of the “Me Too” drugs died with the ARB class going generic. Expect Januvia sales to decline as the meds with CV indication (current and future) take over. Diabetes treatment has gone beyond just A1C lowering.
 






Top Bottom
Back
Quote